Search all trials

Find therapies in clinical trials near you – page 4

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 961
countries: 28
conditions: 2 103

3 961 trials recruiting28 European countries2 103 conditions coveredUpdated today

Quick filters

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Registered drugNo placebo

Study of Elacestrant and Ribociclib for Patients with Endocrine-Responsive HER2-Negative Early Breast Cancer

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Anastrozole

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Registered drugNo placebo

Study Comparing Elacestrant and Standard Endocrine Therapy for Patients with Early Breast Cancer at High Risk of Recurrence

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Anastrozole

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Registered drugNo placebo

Study on Abemaciclib, Letrozole, and Fulvestrant for Patients with Advanced HR-positive/HER2-negative Breast Cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Fulvestrant

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer+1

Not recruiting

Investigational

Study on Niraparib for Patients with HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer with Molecular Disease Detected by ctDNA

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Niraparib Tosilate Monohydrate

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Registered drug

Title: Study of everolimus with hormone therapy in women with high-risk breast cancer (ER-positive, HER2-negative) who are disease-free after initial treatment

Registered drug

Belgium

Participants:18–64 years · 65+ years
Substances:Everolimus

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Registered drugNo placebo

Study on Abemaciclib and Endocrine Therapy for Patients with Advanced Hormone Receptor Positive HER2 Negative Breast Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Abemaciclib

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Registered drugNo placebo

Study Comparing Ribociclib and Palbociclib for Patients with Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Registered drugNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Palbociclib

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Registered drugNo placebo

Study Comparing Trastuzumab Deruxtecan with Chemotherapy for Patients with HER2-Low, Hormone Receptor Positive Breast Cancer After Endocrine Therapy Progression

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Capecitabine

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer+1

Not recruiting

Registered drugNo placebo

Study on Alpelisib and Fulvestrant for Advanced Breast Cancer in Patients with PIK3CA Mutation and Hormone-Receptor Positive, HER2 Negative Tumors

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Alpelisib

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer+1

Not recruiting

Registered drugNo placebo

Study of MEN1611 and Eribulin for Advanced Metaplastic Breast Cancer in Patients with PIK3CA/PTEN Alterations

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Eribulin

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer+4

Not recruiting

Registered drugNo placebo

Study Comparing Ribociclib and Endocrine Therapy to Chemotherapy for Patients with Intermediate-Risk HR+/HER2- Early Breast Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Ribociclib

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Registered drugNo placebo

Study of Ribociclib and Letrozole for Patients with High-Risk Estrogen Receptor-Positive, HER2-Negative Breast Cancer

Registered drugNo placebo

France

Participants:18–64 years
Substances:Letrozole

Contact Research Centre

Find therapies in clinical trials near you – page 4

62 trials match your criteria

Hormone receptor positive HER2 negative breast cancer

Study of Elacestrant and Ribociclib for Patients with Endocrine-Responsive HER2-Negative Early Breast Cancer

Hormone receptor positive HER2 negative breast cancer

Study Comparing Elacestrant and Standard Endocrine Therapy for Patients with Early Breast Cancer at High Risk of Recurrence

Hormone receptor positive HER2 negative breast cancer

Study on Abemaciclib, Letrozole, and Fulvestrant for Patients with Advanced HR-positive/HER2-negative Breast Cancer

Hormone receptor positive HER2 negative breast cancer+1

Study on Niraparib for Patients with HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer with Molecular Disease Detected by ctDNA

Hormone receptor positive HER2 negative breast cancer

Title: Study of everolimus with hormone therapy in women with high-risk breast cancer (ER-positive, HER2-negative) who are disease-free after initial treatment

Hormone receptor positive HER2 negative breast cancer

Study on Abemaciclib and Endocrine Therapy for Patients with Advanced Hormone Receptor Positive HER2 Negative Breast Cancer

Hormone receptor positive HER2 negative breast cancer

Study Comparing Ribociclib and Palbociclib for Patients with Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Hormone receptor positive HER2 negative breast cancer

Study Comparing Trastuzumab Deruxtecan with Chemotherapy for Patients with HER2-Low, Hormone Receptor Positive Breast Cancer After Endocrine Therapy Progression

Hormone receptor positive HER2 negative breast cancer+1

Study on Alpelisib and Fulvestrant for Advanced Breast Cancer in Patients with PIK3CA Mutation and Hormone-Receptor Positive, HER2 Negative Tumors

Hormone receptor positive HER2 negative breast cancer+1

Study of MEN1611 and Eribulin for Advanced Metaplastic Breast Cancer in Patients with PIK3CA/PTEN Alterations

Hormone receptor positive HER2 negative breast cancer+4

Study Comparing Ribociclib and Endocrine Therapy to Chemotherapy for Patients with Intermediate-Risk HR+/HER2- Early Breast Cancer

Hormone receptor positive HER2 negative breast cancer

Study of Ribociclib and Letrozole for Patients with High-Risk Estrogen Receptor-Positive, HER2-Negative Breast Cancer

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.